White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1162-1172. doi: 10.1016/j.cgh.2017.03.021. Epub 2017 Mar 23.

Authors

Michael F Vaezi¹, John E Pandolfino², Marcelo F Vela³, Nicholas J Shaheen⁴

Affiliations

¹ Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: michael.vaezi@vanderbilt.edu.
² Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona.
⁴ Division of Gastroenterology & Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

PMID: 28344064
DOI: 10.1016/j.cgh.2017.03.021

No abstract available

Publication types

Consensus Development Conference

MeSH terms

Baclofen / therapeutic use
Biopsy
Endoscopy, Gastrointestinal
Esophageal pH Monitoring / methods
Esophagitis / classification
Esophagogastric Junction / physiopathology
Esophagus / pathology
Gastroesophageal Reflux / diagnosis*
Gastroesophageal Reflux / therapy*
Hernia, Hiatal / complications
Humans
Laryngoscopy
Manometry
Muscle Relaxants, Central / therapeutic use
Patient Reported Outcome Measures
Phenotype
Precision Medicine
Proton Pump Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Severity of Illness Index
Surveys and Questionnaires
Transcutaneous Electric Nerve Stimulation

Substances

Muscle Relaxants, Central
Proton Pump Inhibitors
Baclofen